AlphAIalphai — Financial news for AI agents
tickerreport.comMAY 302 min read$VRAX

Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Up 173.2% in May

Virax Biolabs Group (NASDAQ:VRAX) saw short interest rise 173.2% in May, reaching 391,277 shares as of May 15 versus 143,206 on April 30, according to the report. About 16.4% of shares are shorted, with a days-to-cover ratio of 0.1 based on average volume. VRAX traded at $0.19, down $0.02, with heavy volume. Weiss reiterated a “sell (e+)” rating.

Original reporting
tickerreport.com
Published May 30, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 30, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Up 173.2% in May — source image
Source · tickerreport.com
Decision brief

The 30-second read

$VRAXBearishMed
01

Why it matters

This is primarily a positioning/flow update. Higher short interest can pressure borrow/cover behavior and raise intraday volatility, but the article does not cite any new clinical, regulatory, or financing event that would re-rate the business.

02

Market read

Traders may treat VRAX as higher-volatility/short-squeeze-risk until the next covering window, while still acknowledging no new fundamental catalyst is provided.

03

What to watch

Days-to-cover is based on average daily volume; if liquidity changes or volume spikes, squeeze dynamics can differ materially from the static ratio.

Relevance 7/10Novelty 8/10Timing: after May short-interest print (as of May 15)

Background

The piece is a short-interest update: May 15 short interest rose to 391,277 shares (+173.2% vs April 30), implying 16.4% of shares are short and days-to-cover is 0.1.

Company-level read

Ticker impact

$VRAXBearishMedium confidence
Context

Article reports May short interest for Virax Biolabs (VRAX) jumped 173.2%, with 16.4% of shares shorted and 0.1 days-to-cover.

Expected impact

Near-term volatility risk skewed higher; direction depends on whether shorts add/cover and whether price holds above recent lows.

Evidence & confidence

The only new datapoint is the short-interest change; without accompanying news (trial, financing, contract), the impact is primarily positioning-driven rather than fundamentals-driven.

Market effects

Sector

For small-cap clinical-stage biotech, short-interest spikes can amplify momentum/volatility around any future catalyst.

Regional

Limited; company is NASDAQ-listed despite Australia HQ.

Global

Low; positioning signal is company-specific.

Counterpoint

What could challenge this read

A short-interest spike can reflect deteriorating fundamentals or dilution risk rather than an imminent squeeze.

Key entities

  • company
    Virax Biolabs Group Limited

    NASDAQ-listed clinical-stage biotech whose short interest increased sharply in May.

Read at source← All news

Related articles

JUL 10
$VRAXMed

Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch

Biotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.

rttnews.com6 min
JUL 9
$VRAXMedAI 8/10

Virax Biolabs Stock Soars 246% On Exclusive Southeast Asia Supply Deal

Virax Biolabs Group Limited (VRAX) shares rose about 246% to $10.99 after the company said it signed an exclusive multi-country supply agreement with Fosun Diagnostics for its ImmuneSelect research-use immune profiling products. The deal covers Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, with near-term revenue via purchase orders.

rttnews.com2 min
JUL 9
$VRAXMed

Why Did Virax Biolabs Stock Triple In One Session? - Virax Biolabs Group (NASDAQ:VRAX)

Virax Biolabs Group (NASDAQ:VRAX) shares surged 228.13% to $10.43 after the company announced an exclusive supply agreement with Fosun Diagnostics covering six Southeast Asian markets. The deal provides immediate product supply via purchase orders and targets near-term revenue, including tuberculosis-related RUO research in Thailand. VRAX also completed a 1-for-25 share consolidation.

benzinga.com3 min
JUL 9
$VRAXMed

Virax Signs Multi-Country Commercial Supply Agreement With Fosun Diagnostics; Stock Skyrockets

Virax Biolabs Group (VRAX) said its subsidiary Virax Biolabs (UK) signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling products. The deal covers Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia, with supply via purchase orders. Fosun Diagnostics is part of Fosun Medtech, and VRAX shares rose on the news.

rttnews.com3 min
JUL 9
$VRAXMed

Virax Biolabs stock surges 100% on Fosun supply deal By Investing.com

Virax Biolabs Group (NASDAQ:VRAX) shares jumped 100% after it signed an exclusive multi-country supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling products. The deal covers six ASEAN markets and enables immediate supply via purchase orders, with initial focus on tuberculosis research in Thailand. ImmuneSelect is research-use-only, separate from Virax’s in-development diagnostic platform.

investing.com4 min